Lung cancer – erlotinib

ERLOTINIB

NICE Appraisal

TA162 Erlotinib for the treatment of non-small cell lung cancer (November 2008)

DSU Reports

Erlotinib for the treatment of non-small cell lung cancer: Report from the Decision Support Unit in response to additional data submitted by Roche (January 2008)

The risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel (December 2007)

Related publications

A Wailoo, A Sutton, A Morgan, The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: a systematic review and meta-analysis 2009 British Journal of Cancer Vol 100: 436-441